Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Completed
Cumberland Pharmaceuticals
Phase 2
2003-06-01
Serious infections caused by resistant bacteria are becoming more of a medical problem
throughout the world. One of the ways to deal with this problem is to develop new drugs that
can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control
infections and whether this drug can be safely given to patients.
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Completed
Theravance Biopharma Antibiotics, Inc.
Phase 2
2003-06-01
Serious infections caused by resistant bacteria are becoming more of a medical problem
throughout the world. One of the ways to deal with this problem is to develop new drugs that
can control these bacteria. This study will measure how well TD-6424 (Telavancin) can control
infections and whether this drug can be safely given to patients.
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Completed
Cumberland Pharmaceuticals
Phase 2
2003-08-01
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety
administered to patients with bloodstream infections and whether telavancin is effective in
treating these infections.
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
Completed
Theravance Biopharma Antibiotics, Inc.
Phase 2
2003-08-01
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety
administered to patients with bloodstream infections and whether telavancin is effective in
treating these infections.
Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Completed
Cumberland Pharmaceuticals
Phase 2
2004-02-01
Serious infections caused by resistant bacteria are becoming more of a medical problem
throughout the world. This study will measure how well TD-6424 (Telavancin) can control
infections and whether the drug is safe to give to patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
